The 2022 Guidelines recommend considering the use of PTH replacement therapy when conventional therapy is deemed unsatisfactory because of inadequate control of biochemical and clinical parameters (ie, symptomatic hypocalcemia, hyperphosphatemia, renal insufficiency, hypercalciuria, and poor quality of life), malabsorption or intolerance of large doses of vitamin D and calcium, or the requirement of high doses of conventional therapy (3). Here, PTH is linked to Hypocalcemia.